Eckert & Ziegler Cuts Dividend for Future Investments, Forecasts 2024 Earnings Growth

• Eckert & Ziegler SE has decided to reduce its dividend to €0.05 per share to finance future investments
• The retained liquidity will be used to finance new high-return projects in the radiopharmaceuticals market, including the expansion of global production capacities
• The dividend reduction is also aimed at ensuring greater independence from external financing
• EZAG shareholders will receive one additional Pentixapharm share for each EZAG share in the planned split-off of Pentixapharm AG
• In the 2023 financial year, the Eckert & Ziegler Group increased sales by 11% to €246.1 million with a net profit of €26.3 million
• For the 2024 financial year, the Executive Board expects sales of just under €265 million and EBIT from continuing operations before one-off effects of around €50 million.

The next important date, Publication Annual Financial Report, at Eckert & Ziegler is on 22.03.2024.

The price of Eckert & Ziegler at the time of the news was 38,22EUR and was up +0,26 % compared with the previous day.
16 minutes after the article was published, the price was 37,20EUR this corresponds to a minus of -2,67 % since publication.
At this time, the index SDAX was at 13.861,05PKT (-0,16 %).

Eckert & Ziegler

+0,91 %

+17,56 %

+34,46 %

+7,24 %

-6,25 %

-40,00 %

+86,48 %

+588,32 %

+1.037,68 %

ISIN:DE0005659700WKN:565970

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max